Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2017

Open Access 01-06-2017

Platelets and cancer angiogenesis nexus

Authors: Marek Z. Wojtukiewicz, Ewa Sierko, Dominika Hempel, Stephanie C. Tucker, Kenneth V. Honn

Published in: Cancer and Metastasis Reviews | Issue 2/2017

Login to get access

Abstract

There has been remarkable insight into the importance of platelets in a wide range of pathophysiologic events, including inflammation and cancer progression. Thrombocytosis in cancer patients is a common finding. Tumor cells induce platelet activation and subsequent aggregation through direct and indirect mechanisms. Platelets are recognized to contribute to metastatic dissemination. There is plenty of evidence that components of the hemostatic system contribute to the process of angiogenesis. Furthermore, there are accumulated data on the substantial influence of blood platelets in the process of blood vessel formation during malignancy. Platelets appear to be the main physiologic transporters of proangiogenic and antiangiogenic factors. Moreover, they influence the process of angiogenesis through platelet-derived microparticles, microRNA, lipids, and variety of surface receptors. Platelets contribute to early and late stages of angiogenesis. Available data support the overall stimulatory effect of platelets on tumor angiogenesis. It raises the possibility that interfering with platelet function may be an effective antineoplastic treatment strategy.
Literature
1.
Bizzozero, J. (1882). Űber einen neunen formbestandteil des blutes und dessen rolle bei der thrombose und blutgerinnung. Virchows Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin, 90, 262–332.
2.
Geatano, G. (2001). Historical overview of the role of platelets in hemostasis and thrombosis. Heamatologica, 86, 349–356.
3.
Billroth, T. (1878). Lectures on surgical pathology and therapeutics: a new handbook for students and practitioners (p. 355). London: The New Sydenham Society.
4.
Mac Kay, W. (1930). The blood platelet: its clinical significance. Quartely Journal of Medicine, 24, 285–293.
5.
Zacharski, L. R., Wojtukiewicz, M. Z., Costantini, V., Ornstein, D. L., & Memoli, V. A. (1992). Pathways of coagulation/fibrinolysis activation in malignancy. Seminars in Thrombosis and Hemostasis, 18, 104–116.PubMedCrossRef
6.
Miller, S. P., Sanchez-Avalos, J., Stefanski, T., & Zuckerman, L. (1967). Coagulation disorders in cancer I. Clinical and laboratory studies. Cancer, 20, 1452–1465.PubMedCrossRef
7.
Edwards, R. L., Rickles, F. R., Moritz, T. E., Henderson, W. G., Zacharski, L. R., Forman, W. B., et al. (1987). Abnormalities of blood coagulation tests in patients with cancer. American Journal of Clinical Pathology, 88, 596–602.PubMedCrossRef
8.
Rickles, F. R., Levine, M., & Edwards, R. L. (1992). Hemostatic alterations in cancer patients. Cancer Metastasis Review, 11, 237–248.CrossRef
9.
Francis, J. L., Biggerstaff, J., & Amirkhosravi, A. (1998). Hemostasis and malignancy. Seminars in Thrombosis and Hemostasis, 24, 93–109.PubMedCrossRef
10.
Wojtukiewicz, M. Z., Sierko, E., & Kisiel, W. (2007). The role of hemostatic system inhibitors in malignancy. Seminars in Thrombosis and Hemostasis, 33, 621–641.PubMedCrossRef
11.
Costantini, V., Zacharski, L. R., Moritz, T. E., & Edwards, R. L. (1990). The platelet count in carcinoma of the lung and colon. Thrombosis and Haemostasis, 64, 501–505.PubMed
12.
Moller-Pedresen, L., & Milman, N. (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. European Respiratory Journal, 9, 1826–1830.CrossRef
13.
Ikeda, M., Furukawa, H., Imamura, H., Shimizu, J., Ishida, H., Masutani, S., et al. (2002). Poor prognosis associated with thrombocytosis in patients with gastric cancer. Annals of Surgical Oncology, 9, 287–291.PubMedCrossRef
14.
Symbas, N. P., Townsend, M. F., El, G. R., Keane, T. E., Graham, S. D., & Petros, J. A. (2000). Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU International, 86, 203–207.PubMedCrossRef
15.
Ribeiro, M., Ruff, P., & Falkson, G. (1997). Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. American Journal of Clinical Oncology, 20, 605–608.PubMedCrossRef
16.
Lopez, A., Daras, V., Cross, P. A., Robertson, G., Beynon, G., & Monaghan, J. M. (1994). Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer, 74, 90–92.CrossRef
17.
Gücer, F., Moser, F., Tamussino, K., Reich, O., Haas, J., Arikan, G., et al. (1998). Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecologic Oncology, 70, 210–214.PubMedCrossRef
18.
Zeimet, A. G., Marth, C., Muller Holzner, E., Daxenbichler, G., & Dapunt, O. (1994). Significance of thrombocytosis in patients with epithelial ovarian cancer. American Journal Obstetrics & Gynecology, 170, 549–554.CrossRef
19.
Nakano, T., Fujii, J., Tamura, S., Hada, T., & Higashino, K. (1986). Thrombocytosis in patients with malignant mesothelioma. Cancer, 58, 1699–1701.PubMedCrossRef
20.
Gao, L., Zhang, H., Zhang, B., Zhang, L., & Wang, C. (2017). Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer. Oncotarget. doi:10.​18632/​oncotarget.​14921.
21.
Wang, Y. H., Deng, S. J., Yang, Y. D., Yao, N., Zhao, J. M., Min, G. T., et al. (2017). The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Biomarkers in Medicine, 11(2), 195–210.PubMedCrossRef
22.
Schwartz, R. E. (1999). Platelet counts and prognosis of pancreatic cancer. Lancet, 353, 2158–2159.CrossRef
23.
Slichter, S. J., & Harker, L. A. (1974). Hemostasis in malignancy. Annals of the New York Academy of Sciences, 230, 252–262.PubMedCrossRef
24.
Tang, D. G., & Honn, K. V. (1994-1995). Adhesion molecules and tumor metastasis: an update. Invasion & Metastasis, 14, 109–122.
25.
Honn, K. V., Tang, G. T., & Chen, Y. Q. (1992). Platelets and cancer metastasis: more than an epiphenomenon. Seminars in Thrombosis and Hemostasis, 18, 392–415.PubMedCrossRef
26.
Gasic, G. J., Gasic, T. B., & Steward, C. C. (1968). Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences USA, 61, 46–52.CrossRef
27.
Nierodzik, M. L., Klepfish, A., & Karpatkin, S. (1995). Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thrombosis and Haemostasis, 74, 282–290.PubMed
28.
Dvorak, H. F. (1986). Tumors: wounds that do not heal. New England Journal of Medicine, 315, 1650–1659.PubMedCrossRef
29.
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. New England Journal Medicine, 285, 1182–1186.CrossRef
30.
Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Medicine, 1, 27–31.PubMedCrossRef
31.
32.
Zacharski, L. R., Constantini, V., Wojtukiewicz, M. Z., Memoli, V. A., & Kudryk, B. J. (1990). Anticoagulants as cancer therapy. Seminars in Oncology, 17, 217–227.PubMed
33.
Sierko, E., & Wojtukiewicz, M. Z. (2004). Platelets and angiogenesis in malignancy. Seminars in Thrombosis and Hemostasis, 30, 95–108.PubMedCrossRef
34.
Wojtukiewicz, M. Z., Sierko, E., & Rak, J. (2004). Contribution of hemostatic system to angiogenesis in cancer. Seminars in Thrombosis and Hemostasis, 30, 5–20.PubMedCrossRef
35.
Sierko, E., Wojtukiewicz, M. Z., Zimnoch, L., Brekken, R., Thorpe, P., & Kisiel, W. (2011). Co-localization of prothrombin fragment F1+2 and VEGFR-2 bound VEGF in human colon cancer. Anticancer Research, 31, 843–847.PubMed
36.
D’Asti, E., Huang, A., Kool, M., Meehan, B., Chan, J. A., Jabado, N., et al. (2016). Tissue factor regulation by miR-520g in primitive neuronal brain tumor cells: a possible link between oncomirs and the vascular tumor microenvironment. American Journal of Pathology, 186(2), 446–459.PubMedCrossRef
37.
D’Asti, E., Kool, M., Pfister, S. M., & Rak, J. (2014). Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. Journal of Thrombosis and Haemostasis., 2(11), 1838–1849.CrossRef
38.
Verheul, H. M. W., Hoekman, K., Luykx-de Bakkerr, E., Eekm, C. A., Folman, C. C., Broxterman, H. J., & Pinedo, H. M. (1997). Platelet transporter of vascular endothelial growth factor. Clinical Cancer Research, 3, 2187–2190.PubMed
39.
Wartiovaara, U., Salven, P., & Mikkola Heta, I. (1998). Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thrombosis Haemostasis, 80, 171–175.PubMed
40.
Verheul, H. M. W., Hoekman, K., Lupu, F., Broxterman, H. J., van der Valk, P., Kakkar, A. K., & Pinedo, H. M. (2000). Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clinical Cancer Research, 6, 166–171.PubMed
41.
Möhle, R., Green, D., Moore, R. L., Nachman, R. L., & Raffi, S. (1997). Constitutive production of thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proceedings of the National Academy of Sciences USA, 94, 663–669.CrossRef
42.
Pipli-Synestos, E., Papadimitriou, E., & Maragoudakis, M. E. (1998). Evidence that platelets promote tube formation by endothelial cells on Matrigel. British Journal of Pharmacology, 125, 1252–1257.CrossRef
43.
Kisucka, J., Butterfield, C.E., Duda, D.G., Eichenberger, S.C., Saffaripour, S., & Ware, J. (2006). Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proceedings of the National Academy of Sciences USA, 103, 855-860.
44.
Andrews, R. K., Shen, Y., Gardiner, E. E., & Berndt, M. C. (2001). Platelet adhesion receptors and (patho)physiological thrombus formation. Histology and Histopathology, 16, 969–980.PubMed
45.
Chen, H., Locke, D., Liu, Y., & Kahn, M. L. (2002). The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. The Journal of Biological Chemistry, 277, 3011–3019.PubMedCrossRef
46.
Kamata, T., & Takada, Y. (2001). Platelet integrin alphaIIbbeta3-ligand interactions: what we learn from the structure? International Journal of Hematology, 74, 382–389.PubMedCrossRef
47.
Coughlin, S. R. (1999). Protease-activated receptors and platelet function. Thrombosis and Haemostasis, 82, 353–356.PubMed
48.
Di Virgilio, F., Chiozzi, P., Ferrari, D., Falzoni, S., Sanz, J. M., Morelli, A., et al. (2001). Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood, 97, 587–600.PubMedCrossRef
49.
Ruggeri, Z. M., & Mendolicchio, G. L. (2007). Adhesion mechanisms in platelet function. Circulation Research, 100(12), 1673–1685.PubMedCrossRef
50.
Farndale, R. W. (2006). Collagen-induced platelet activation. Blood Cells, Molecules and Diseases, 36, 162–165.PubMedCrossRef
51.
Fredrickson, B. J., Dong, J. F., McIntire, L. V., & Lopez, J. A. (1998). Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood, 92, 449–461.
52.
Heemskerk, J. W. M., Bevers, E. M., & Lindhout, T. (2002). Platelet activation and blood coagulation. Thrombosis and Heamostasis, 88, 186–193.
53.
Hartwig, J. M., & DeSisto, M. (1991). The cytoskeleton of the resting human blood platelets: structure of the membrane skeleton and its attachment to actin filaments. The Journal of Cell Biology, 112, 407–425.PubMedCrossRef
54.
Serrano, K., & Devine, D. V. (2002). Intracellular factor XIII crosslinks platelet cytoskeletal elements upon platelet activation. Thrombosis and Haemostasis, 88, 315–320.PubMed
55.
Thon, J. N., & Italiano, J. E. (2012). Platelets: production, morphology and ultrastructure. Handbook of Experimental Pharmacology, 210, 3–22.CrossRef
56.
Rendu, F., & Brohard-Bohn, B. (2001). The platelet release reaction: granules’ constituents, secretion and functions. Platelets, 12, 261–273.PubMedCrossRef
57.
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Review, 33(1), 231–269.CrossRef
58.
Kato, N., Yasukawa, K., Onozuka, T., & Kimura, K. (1999). Paraneoplastic syndromes of leukocytosis, thrombocytosis, and hypercalcemia associated with squamous cell carcinoma. Journal of Dermatology, 26, 352–358.PubMedCrossRef
59.
Estrov, A., Talpaz, M., Mavlight, G., Pazdur, R., Harris, D., Greenberg, S. M., et al. (1995). Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. American Journal of Medicine, 98, 551–558.PubMedCrossRef
60.
Gastl, G., Plante, M., Finstad, C. L., Wong, G. Y., Federici, M. G., Bander, N. H., et al. (1993). High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. British Journal of Haematology, 83, 433–441.PubMedCrossRef
61.
Suzuki, A., Takahashi, T., Nakamura, K., Tsuyuoka, R., Okuno, Y., Enomoto, T., et al. (1992). Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood, 80, 2052–2059.PubMed
62.
Rafi, S., Shapiro, F., Pettengeli, R., Ferris, B., Nachman, R. L., Moore, M. A., et al. (1995). Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood, 86, 3353–3363.
63.
Higashihara, M., Sunaga, S., Tange, T., Oohashi, H., & Kurokawa, K. (1992). Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombosis. Cancer, 70, 2105–2108.PubMedCrossRef
64.
Uppenkamp, M., Makarove, E., Petrasch, S., & Brittinger, G. (1998). Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Annals of Hematology, 77, 217–223.PubMedCrossRef
65.
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Dong, H. H., Bottsford-Miller, J., et al. (2013). Paraneoplastic thrombocytosis in ovarian cancer. The New England Journal of Medicine, 366, 610–618.CrossRef
66.
Sasaki, Y., Takahashi, T., Miyazaki, H., Matsumoto, A., Kato, T., Nakamura, K., et al. (1999). Production of thrombopoietin by human carcinomas and its novel isoforms. Blood, 94, 1952–1960.PubMed
67.
Baj-Krzyworzecka, M., Majka, M., Pratico, D., Ratajczak, J., Vilaire, G., Kijowski, J., et al. (2002). Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Experimental Hematology, 30, 450–459.CrossRef
68.
Rafi, S., Mohle, R., Shapiro, F., Frey, B. M., & Moore, M. A. (1997). Regulation of hematopoiesis by microvascular endothelium. Leukemia & Lymphoma, 27, 375–386.CrossRef
69.
Wickenhauser, C., Lorenzen, J., Thiele, J., Hillienhof, A., Jungheim, K., Schmitz, B., et al. (1995). Secretion of cytokines (interleukines-1 alpha, -3, and granulocyte-macrophage colony stimulating factor) by normal human bone marrow megakaryocytes. Blood, 85, 685–691.PubMed
70.
Jones, C. L., Witte, D. P., Feller, M. J., Fugman, D. A., Dorn, G. W., Liebermann, M., & A. (1992). Response of human megakaryocytic cell line to thrombin: Increase in intracellular free calcium and mitogen release. Biochimica et Biophysica Acta, 1136, 272–282.PubMedCrossRef
71.
Avraham, H., Banu, N., Scadden, D. T., Abraham, J., & Groopman, J. E. (1994). Modulation of megakaryocytopoiesis by human basic fibroblast growth factor. Blood, 83, 2126–2132.PubMed
72.
Broxmeyer, H. E., Cooper, S., Li, Z. H., Lu, L., Song, H. Y., Kwon, B. S., et al. (1995). Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. International Journal of Hematology, 62, 203–215.PubMedCrossRef
73.
Tavasolli, M., & Aoki, M. (1989). Localization of megakaryocytes in the bone marrow. Blood Cells, 15, 3–14.
74.
Feng, W., Madajka, M., Kerr, B. A., Mahabeleshwar, G. H., Whiteheart, S. W., & Byzova, T. V. (2011). A novel role for platelet secretion in angiogenesis: mediating bone marrow–derived cell mobilization and homing. Blood, 117(14), 3893–3902.PubMedPubMedCentralCrossRef
75.
Salgado, R., Vermeulen, P. B., Benoy, I., Weytjens, R., Huget, P., Van Marck, E., & Dirix, L. Y. (1999). Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. British Journal of Cancer, 80, 892–897.PubMedPubMedCentralCrossRef
76.
Yang, M., Li, K., Ng, M. H., Yuen, P. M., Fok, T. F., Li, C. K., et al. (2003). Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36. Thrombosis Research, 109, 47–54.PubMedCrossRef
77.
Bikfalvi, A., & Han, Z. C. (1994). Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia, 8, 523–529.PubMed
78.
Falanga, A., & Rickles, F. R. (1999). Pathophysiology of the thrombophilic state in the cancer patient. Seminars in Thrombosis and Hemostasis, 25, 173–182.PubMedCrossRef
79.
Kitagawa, H., Yamamoto, N., Yamamoto, K., Tanoue, K., Kosaki, G., & Yamazaki, H. (1989). Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and –independent platelet aggregations induced by tumor cells. Cancer Research, 49, 537–541.PubMed
80.
Wehmeier, A., Tschope, D., Esser, J., Menzel, C., Nieuwenhuis, H. K., & Schneider, W. (1991). Circulating activated platelets in myeloproliferative disorders. Thrombosis Research, 61(3), 271–278.PubMedCrossRef
81.
Blann, A. D., Gurney, M., Wadley, D., Bareford, D., Stonelake, P., & Lip, G. Y. (2001). Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagulation and Fibrinolysis, 12(1), 43–50.PubMedCrossRef
82.
Caine, G. J., Lip, G. Y., & Blann, A. D. (2004). Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Annals of Medicine, 36(4), 273–277.PubMedCrossRef
83.
Wu, L. Q., Zhang, W. J., Niu, J. X., Ye, L. X., Yang, Z. H., Grau, G. E., & Lou, J. N. (2008). Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. Journal of Vascular Research, 45, 78–86.PubMedCrossRef
84.
85.
Jurasz, P., Alonso-Escolano, D., & Radomski, M. W. (2004). Platelet-cancer interactions: mechanisms and pharmacology of tumor-cell-induced platelet aggregation. British Journal of Pharmacology, 143, 819–826.PubMedPubMedCentralCrossRef
86.
Bastida, E., Ordinas, A., Giardina, S., & Jamieson, G. A. (1982). Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Research, 42(11), 4348–4352.PubMed
87.
Raica, M., Cimpean, A. M., & Ribatti, D. (2008). The role of podoplanin in tumor progression and metastasis. Anticancer Research, 28, 2997–3006.PubMed
88.
Dang, Q., Liu, J., Li, J., & Sun, Y. (2014). Podoplanin: a novel regulator of tumor invasion and metastasis. Medical Oncology, 31(9), 24–29.PubMedCrossRef
89.
Lowe, K. L., Navarro-Nunez, L., & Watson, S. P. (2012). Platelet CLEC-2 and podoplanin in cancer metastasis. Thrombosis Research, 129(suppl 1), S30–S37.PubMedCrossRef
90.
91.
Demers, M., Krause, D. S., Schatzberg, D., Martinod, K., Voorhees, J. R., Fuchs, T. A., et al. (2012). Cancer predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proceedings of the National Academy of Sciences USA, 109, 13076-13081.
92.
Karpatkin, S., Nierodzik, M. L., & Klepfish, A. (1996). A role of platelets, thrombin in cancer. Vessels, 2, 17–23.
93.
Pinedo, H. M., Verhaul, H. M. W., D’Amato, R. J., & Folkman, J. (1998). Involvement of platelets in tumor angiogenesis? Lancet, 352(9142), 1775–1777.PubMedCrossRef
94.
Verheul, H. M. W., Jorna, A. S., Hoekman, K., Broxterman, H. J., Gebbink, M. F., & Pinedo, H. M. (2000). Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood, 96(13), 4216–4221.PubMed
95.
Slupsky, J. R., Kalbas, M., Willuwelt, A., Henn, V., Kroczek, R. A., & Müller-Berghaus, G. (1998). Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thrombosis and Haemostasis, 80(6), 1008–1014.PubMed
96.
Karmann, K., Min, W., Fanslow, W.C., & Pober, J. S. (1996), Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. Journal of Experimental Medicine,184(1), 173-182.
97.
Rafii, D. C., Psaila, B., Butler, J., Jin, D. K., & Lyden, D. (2008). Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow–derived cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 217–222.PubMedCrossRef
98.
Klement, G. L., Yip, T. T., Cassiola, F., Kikuchi, L., Cervi, D., Podust, V., et al. (2009). Platelets actively sequester angiogenesis regulators. Blood, 113, 2835–2842.PubMedCrossRef
99.
Kuznetsov, H. S., Marsh, T., Markens, B. A., Castaño, Z., Greene-Colozzi, A., Hay, S. A., et al. (2012). Identification of luminal breast cancers that establish a tumor-supportive microenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discovery, 2, 1150–1165.PubMedPubMedCentralCrossRef
100.
Best, M. G., Sol, N., Kooi, I., Tannous, B. A., Wesseling, P., & Wurdinger, T. (2015). RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell, 28, 666–676.PubMedPubMedCentralCrossRef
101.
Banks, R. E., Forbes, M. A., Kinsey, S. E., Stanley, A., Ingham, E., Walters, C., et al. (1998). Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. British Journal of Cancer, 77, 956–964.PubMedPubMedCentralCrossRef
102.
Caine, G. J., Lip, G. Y., Stonelake, P. S., Ryan, P., & Blann, A. D. (2004). Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thrombosis and Haemostasis, 92, 185–190.PubMed
103.
McDowell, G., Temple, I., Li, C., Kirwan, C. C., Bundred, N. J., McCollum, C. N., et al. (2005). Alteration in platelet function in patients with early breast cancer. Anticancer Research, 25, 3963–3966.PubMed
104.
Werther, K., Christensen, I. J., & Nielsen, H. J. (2002). Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of various leukocytes and platelets. Scandinavian Journal of Clinical and Laboratory Investigation, 62, 343–350.PubMedCrossRef
105.
Jelkman, W. (2001). Pitfalls in the measurement of circulating vascular endothelial growth factor. Clinical Chemistry, 47, 617–623.
106.
Kim, S. J., Choi, I. K., Park, K. H., Yoon, S. Y., Oh, S. C., Seo, J. H., et al. (2004). Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Journal of Clinical Oncology, 34, 184–190.
107.
Brekken, R. A., Huang, X., King, S. W., & Thorpe, P. E. (1998). Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Research, 58, 1952–1959.PubMed
108.
Chen, F. H., Crist, S. A., Zhang, G. J., Iwamoto, Y., & See, W. A. (2002). Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmatte-Guerin through nuclear factor-kappaB and Ap-1 via an early pathway. Journal of Urology, 168, 786–797.PubMedCrossRef
109.
Brock, T. A., Dvorak, H. F., & Senger, D. R. (1991). Tumor secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human cells. American Journal of Pathology, 138, 213–221.PubMedPubMedCentral
110.
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., et al. (2000). Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Medicine, 6, 460–463.PubMedCrossRef
111.
Wojtukiewicz, M. Z., Hempel, D., Sierko, E., Tucker, S. C., & Honn, K. V. (2016). Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis. Cancer Metastasis Review, 35(2), 213–233.CrossRef
112.
Wojtukiewicz, M. Z., Hempel, D., Sierko, E., Tucker, S. C., & Honn, K. V. (2015). Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis. Cancer Metastasis Review, 34(4), 775–796.CrossRef
113.
Clauss, M., Gerlach, M., Gerlach, H., Brett, J., Wang, F., Familletti, P. C., et al. (1990). Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. The Journal of Experimental Medicine, 172(6), 1535–1545.PubMedCrossRef
114.
Ma, L., Perini, R., McKnight, W., Klein, A., Hollenberg, M.D., & Wallace, J.L. (2005). Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proceedings of the National Academy of Sciences USA, 102, 216-220.
115.
Wijelath, E. S., Murray, J., Rahman, S., Patel, Y., Ishida, A., Strand, K., et al. (2002). Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circulation Research, 91(1), 25–31.PubMedCrossRef
116.
Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539–545.PubMedCrossRef
117.
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development, 13(11), 1382–1397.CrossRef
118.
McMahon, G. A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M. K., Westrick, R. J., et al. (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. The Journal of Biological Chemistry, 276(36), 33964–33968.PubMedCrossRef
119.
Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., et al. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Medicine, 4(8), 923–928.PubMedCrossRef
120.
Peterson, J. E., Zurakowski, D., Italiano Jr., J. E., Michel, L. V., Connors, S., Oenick, M., D’Amato, R. J., et al. (2012). VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis, 15(2), 265–273.PubMedCrossRef
121.
Browder, T., Folkman, J., & Pirie-Shepherd, S. (2000). The hemostatic system as a regulator of angiogenesis. The Journal of Biological Chemistry, 275(3), 1521–1524.PubMedCrossRef
122.
Jurasz, P., Alonso, D., Castro-Blanco, S., Murad, F., & Radomski, M. W. (2003). Generation and role of angiostatin in human platelets. Blood, 102(9), 3217–3223.PubMedCrossRef
123.
Jurasz, P., Santos-Martinez, M. J., Radomska, A., & Radomski, M. W. (2006). Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. Journal of Thrombosis and Haemostasis, 4(5), 1095–1106.PubMedCrossRef
124.
McEver, R. P. (2001). Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thrombosis and Haemostasis, 86(3), 746–756.PubMed
125.
Mast, A. E., Stadanlick, J. E., Lockett, M., Dietzen, D. J., Hasty, K. A., & Hall, C. L. (2000). Tissue factor pathway inhibitor binds to platelet thrombospondin-1. The Journal of Biological Chemistry., 275(41), 31715–31721.PubMedCrossRef
126.
Selheim, F., Fukami, M. H., Holmsen, H., & Vessbotn, F. S. (2000). Platelet-derived-growth-factor-induced signalling in human platelets: phosphoinositide-3-kinase-dependent inhibition of platelet activation. Biochemical Journal, 350, 469–475.PubMedPubMedCentralCrossRef
127.
Chui, C. M., Li, K., Yang, M., Chuen, C. K., Fok, T. F., Li, C. K., et al. (2003). Platelet-derived growth factor up-regulates the expression of transcription factors NF-E2, GATA-1 and c-Fos in megakaryocytic cell lines. Cytokine, 21(2), 51–64.PubMedCrossRef
128.
Teuscher, E., & Weidlich, V. (1985). Adenosine nucleotides, adenosine and adenine as angiogenesis factors. Biomedica Biochimica Acta, 44, 493–495.PubMed
129.
English, D., Welch, Z., Kovala, A. T., Harvey, K., Volpert, O. V., Brindley, D. N., et al. (2000). Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB Journal, 14, 2255–2265.PubMedCrossRef
130.
Freyssinet, J. M. (2003). Cellular microparticles: what are they bad or good for? Journal of Thrombosis and Haemostasis, 1, 1655–1662.PubMedCrossRef
131.
Rhee, J. S., Black, M., Schubert, U., Fischer, S., Morgenstern, E., Hames, H. P., & Preissner, K. T. (2004). The functional role of blood platelet components in angiogenesis. Thrombosis and Hemostasis, 92, 394–402.
132.
Italiano, J. E., Mairuhu, A. T. A., & Fleumen Haft, R. (2010). Clinical relevance of microparticles from platelets and megakaryocytes. Current Opinion in Hematology, 17, 578–584.PubMedPubMedCentralCrossRef
133.
134.
Flumenhaft, R. (2006). Formation and fate of platelet microparticles. Blood Cells, Molecules and Diseases, 36, 182–187.CrossRef
135.
Kim, H. K., Sonfg, K. S., Park, Y. S., Kang, Y. H., Lee, Y. J., Lee, K. R., et al. (2003). Elevated levels of circulating platelet microparticles, VEGF, IL-6, and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer, 39, 184–191.PubMedCrossRef
136.
Ratajczak, J., Wysoczyński-Hajek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia, 20, 1487–1495.PubMedCrossRef
137.
Tan, K. T., & Lip, G. Y. (2005). The potential role of platelet microparticles in atherosclerosis. Thrombosis and Haemostasis, 94, 488–492.PubMed
138.
Kim, H. K., Song, K. S., Chung, J. H., Lee, K. R., & Lee, S. N. (2004). Platelet microparticles induce angiogenesis in vitro. British Journal of Haematology, 124, 374–384.
139.
Brill, A., Dashevsky, O., Rivo, J., Gozal, Y., & Varon, D. (2005). Platelet-derived microparticles induce angiogenesis and stimulate post-ischaemic revascularization. Cardiovascular Research, 67, 30–38.PubMedCrossRef
140.
Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Crtis, L., Machalinski, B., Ratajczak, J., et al. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113, 752–760.PubMedCrossRef
141.
Cloutier, N., Pare, A., Farndale, R. W., Schumacher, H. R., Nigrovic, P. A., Lacroix, S., et al. (2012). Platelets can enhance vascular permeability. Blood, 120, 1334–1343.PubMedCrossRef
142.
Prokopi, M., Pula, G., Mayr, U., Devue, C., Gallagher, J., Xiao, Q., et al. (2009). Proteome analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood, 114, 723–732.PubMedCrossRef
143.
Li, X., & Cong, H. (2009). Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Texas Heart Institute Journal, 36, 134–139.PubMed
144.
Martinez, M. C., & Andriantsitohaina, R. (2011). Microparticles in angiogenesis: therapeutic potential. Circulation Research, 109, 110–119.PubMedCrossRef
145.
Dashevsky, O., Varon, D., & Brill, A. (2009). Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. International Journal of Cancer, 124, 1773–1777.PubMedCrossRef
146.
Seiki, M. (2003). Membrane-type 1 metalloproteinase: a key enzyme for tumor invasion. Cancer Letters, 194, 1–11.PubMedCrossRef
147.
Cocucci, E., Racchetti, G., & Meldolesi, J. (2009). Shedding microvesicles: artefacts no more. Trends in Cell Biology., 19(2), 43–51.PubMedCrossRef
148.
Risitano, A., Beaulieu, L. M., Vitseva, O., & Freedman, J. E. (2012). Platelets and platelet-like particles mediate intercellular RNA transfer. Blood, 119(26), 6288–6295.PubMedPubMedCentralCrossRef
149.
Diehl, P., Fricke, A., Sander, L., Stamm, J., Bassler, N., Htun, N., et al. (2012). Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovascular Research, 93(4), 633–644.PubMedPubMedCentralCrossRef
150.
Herranz, H., & Cohen, S. M. (2010). MicroRNAs and gene regulatory networks: managing the impact of noise in biological system. Genes & Development, 24, 1339–1344.CrossRef
151.
Czech, B., & Hannon, G. J. (2011). Small RNA sorting: matchmaking for argonuates. Nature Reviews Genetics, 12, 19–31.PubMedCrossRef
152.
Denli, A. M., Tops, B. B., Plasterk, R. H., Ketting, R. F., & Hannon, G. J. (2004). Processing of primary microRNA by the microprocessor complex. Nature, 432, 231–235.PubMedCrossRef
153.
Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004). Nuclear export of microRNA precursors. Science, 303, 95–98.PubMedCrossRef
154.
Diederiche, S., & Haber, D. A. (2007). Dual role for argonuates in microRNA processing and posttranscriptional regulation of micro-RNA expression. Cell, 131, 1097–1108.CrossRef
155.
Ghildiyal, M., Xu, J., Seitz, H., Weng, Z., & Zamore, P. D. (2010). Sorting of Drosophila small silencing RNAs partitions microRNA* strands into the RNA interference pathway. RNA, 16, 43–56.PubMedPubMedCentralCrossRef
156.
Landry, P., Plante, I., Ouellet, D. L., Perron, M. P., Rousseau, G., & Provost, P. (2009). Existence of a microRNA pathway in anucleate platelets. Nature Structural & Molecular Biology, 16(9), 961–966.CrossRef
157.
Ple’, H., Landry, P., Benham, A., Coarfa, C., Gunaratne, P. H., & Provost, P. (2012). The repertoire and features of human platelet microRNAs. PloS One. doi:10.​1371/​journal.​pone.​0050746 Accessed 25 December 2012.
158.
Kondkar, A. A., Bray, M. S., Leal, S. M., Nagalla, S., Liu, D. J., & Jin, Y. (2010). VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. Journal of Thrombosis and Haemostasis, 8(2), 369–378.PubMedCrossRef
159.
Nagalla, S., Shaw, C., Kong, X., Kondkar, A. A., Edelstein, L. C., Ma, L., et al. (2011). Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 117(19), 5189–5197.PubMedPubMedCentralCrossRef
160.
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences USA, 108(12), 5003–5008.CrossRef
161.
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biology, 13(4), 423–433.PubMedPubMedCentralCrossRef
162.
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9(6), 654–659.PubMedCrossRef
163.
164.
Boilard, E., Nigrovic, P. A., Larabee, K., Watts, G. F., Coblyn, J. S., Weinblatt, M. E., et al. (2010). Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science, 327, 580–583.PubMedPubMedCentralCrossRef
165.
Gidlöf, O., van der Brug, M., Ohman, J., Gilje, P., Olde, P., Wahlestedt, C., & Erlinge, D. (2013). Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood, 121, 3908–3917.PubMedCrossRef
166.
Laffont, B., Corduan, A., Plé, H., Duchez, A. C., Cloutier, N., Boilard, E., & Provost, P. (2013). Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood, 122(2), 253–261.PubMedCrossRef
167.
Yi, P., Liang, H., Liu, H., Li, D., Chen, X., Li, L., Zhang, C.-Y., & Zen, K. (2014). Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor1 receptor. Journal of Immunology, 192, 437–446.CrossRef
168.
Nicoli, S., Standley, C., Walker, P., Hurlstone, A., Fogarty, K. E., & Lawson, N. D. (2010). MicroRNA-mediated integration of haemodynamics and Vegf signaling during angiogenesis. Nature, 464, 1196–1200.PubMedPubMedCentralCrossRef
169.
Fish, J. E., Santoro, M. M., Morton, S. U., Yu, S., Yeh, R. F., et al. (2008). miR-126 regulates angiogenic signaling and vascular integrity. Developmental Cell, 15, 272–284.PubMedPubMedCentralCrossRef
170.
Nicolas, F. E., Pais, H., Schwach, F., Lindow, M., Kauppinen, S., Moulton, V., & Dalmay, T. (2008). Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA, 14, 2513–2520.PubMedPubMedCentralCrossRef
171.
Poliseno, L., Tuccoli, A., Mariani, L., Evangelista, M., Citti, L., Woods, K., et al. (2006). MicroRNAs modulate the angiogenic properties of HUVECs. Blood, 108, 3068–3071.PubMedCrossRef
172.
le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., et al. (2007). Regulation of the p27/(Kip1) tumor suppressor by miR-221 and niR-222 promotes cancer cell proliferation. EMBO Journal, 26, 3699–3708.PubMedPubMedCentralCrossRef
173.
Italiano Jr., J. E., Richardson, J. L., Patel-Hett, S., Battinelli, E., Zaslavsky, A., Short, S., et al. (2008). Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood, 111(3), 1227–1233.PubMedPubMedCentralCrossRef
174.
175.
Batinelli, E. M., Markens, B. A., & Italiano Jr., J. E. (2011). Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood, 118, 1359–1369.CrossRef
176.
Bambace, N. M., Levis, J. E., & Holmes, C. E. (2010). The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets, 21, 85–93.PubMedCrossRef
177.
Kamykowski, J., Carlton, P., Sehgal, S., & Storie, B. (2011). Quantitative immunofluorescecnce mapping reveales little functional coclustering of proteins within platelets alpha-granules. Blood, 118, 1370–1378.PubMedCrossRef
178.
Jonnalagadda, D., Izu, L. T., & Whiteheart, S. W. (2012). Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood, 120, 5209–5216.PubMedPubMedCentralCrossRef
179.
Sierko, E., & Wojtukiewicz, M. Z. (2007). Inhibition of platelet function: does it offer a chance of better cancer progression control. Seminars in Thrombosis and Hemostasis, 33, 712–721.PubMedCrossRef
180.
Wojtukiewicz, M. Z., Sierko, E., & Zacharski, L. R. (2004). Interfering with hemostatic system components: possible new approaches to antiangiogenic therapy. Seminars in Thrombosis and Hemostasis, 30, 145–156.PubMedCrossRef
Metadata
Title
Platelets and cancer angiogenesis nexus
Authors
Marek Z. Wojtukiewicz
Ewa Sierko
Dominika Hempel
Stephanie C. Tucker
Kenneth V. Honn
Publication date
01-06-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9673-1

Other articles of this Issue 2/2017

Cancer and Metastasis Reviews 2/2017 Go to the issue

OriginalPaper

Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention

OriginalPaper

Platelet RNA signatures for the detection of cancer

ReviewPaper

Platelet-targeted pharmacologic treatments as anti-cancer therapy

OriginalPaper

The influence of platelet membranes on tumour cell behaviour

OriginalPaper

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

ReviewPaper

Preface
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits